Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid receptor antagonist to a regimen based on inhibition of angiotensin-converting enzyme (ACE) used relatively low doses of ACE inhibitors. Furthermore, these studies did not determine whether antiproteinuric effects were independent of BP lowering. We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily). We randomly assigned the patients to placebo, losartan (100 mg daily), or spironolactone (25 mg daily) for 48 wk. We obtained blood and urine albumin, urea, creatinine, electrolytes, A1c, and ambulatory BP at baseline, 24, and 48 wk. Compared with placebo, the urine albumin-to-creatinine ratio decreased by 34.0% (95% CI, -51.0%, -11.2%, P = 0.007) in the group assigned to spironolactone and by 16.8% (95% CI, -37.3%, +10.5%, P = 0.20) in the group assigned to losartan. Clinic and ambulatory BP, creatinine clearance, sodium and protein intake, and glycemic control did not differ between groups. Serum potassium level was significantly higher with the addition of either spironolactone or losartan. In conclusion, the addition of spironolactone, but not losartan, to a regimen including maximal ACE inhibition affords greater renoprotection in diabetic nephropathy despite a similar effect on BP. These results support the need to conduct a long-term, large-scale, renal failure outcomes trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, mineralocorticoid receptor antagonists reduce albuminuria in people with diabetic nephropathy (82 -84).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, steroidal MRA reduce albuminuria.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, MRAs reduce albuminuria in people with diabetic nephropathy (89)(90)(91).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [90]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, MRAs reduce albuminuria in people with diabetic nephropathy (83–85).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [84]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Lifestyle modi fi cation focusing on weight loss (if indicated); application of a Mediterranean or Dietary Approaches to Stop Hypertension (DASH) eating pattern; reduction of saturated fat and trans fat; increase of dietary n-3 fatty acids, viscous fi ber, and plant stanols/sterols intake; and increased physical activity should be recommended to improve the lipid pro fi le and reduce the risk of d”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Littell, R. C., Milliken, G. A., Stroup, W. W., Wolfinger, R. D., & Schabenberger, O. (2006) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,924
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816 · cited 1×
“(2) proteinuria defined as a 24-h UACR 300 mg/g despite treatment CLINICAL RESEARCH www.”
BackgroundKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
(2018) · The SAGE Encyclopedia of Educational Research, Measurement, and Evaluation · doi:10.4135/9781506326139.n404 · Cited by 1,528
(2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.003 · Cited by 1,245
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
A method for estimating nitrogen intake of patients with chronic renal failure
Maroni, B. J., Steinman, T. I., & Mitch, W. E. (1985) · Kidney International · doi:10.1038/ki.1985.10 · Cited by 780
(2004) · PubMed · Cited by 502
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110919 · Cited by 375
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Pohl, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090763 · Cited by 322 · cited 2×
“5 Triglycerides, mg/dl 183 145–232 175 136–225 191 156–235 Total cholesterol, mg/dl 189 (49) 198 (75) 176 (44) LDL cholesterol, mg/dl 95 (38) 100 (45) 75 (29) HDL cholesterol, mg/dl 43 (10) 46 (15) 45 (11)”
The Mineralocorticoid Receptor: Insights into its Molecular and (Patho)Physiological Biology
Viengchareun, S., Le Menuet, D., Martinerie, L., Munier, M., Tallec, L. P.-L., & Lombès, M. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05012 · Cited by 316
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Zuckerman, A., & Stier, C. T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.232 · Cited by 310
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Andersen, S., Tarnow, L., Rossing, P., Hansen, B. V., & Parving, H.-H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00880.x · Cited by 289
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P., & Parving, H. H. (2006) · Kidney International · doi:10.1038/sj.ki.5001580 · Cited by 215
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 211
Keane, W. F., Zhang, Z., Lyle, P. A., Cooper, M. E., de Zeeuw, D., Grunfeld, J.-P., Lash, J. P., McGill, J. B., Mitch, W. E., Remuzzi, G., et al. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01381005 · Cited by 202 · cited 1×
“4/23 4/22 4/23 24-h ambulatory BP, mmHg Systolic 138 (15) 143 (15) 135 (11) Diastolic 75 (9) 75 (9) 71 (9) Clinical BP, mmHg Systolic 132 (18) 136 (14) 132 (16) Diastolic 74 (9) 72 (11) 73 (10) Prior history of myocardial infarction/CABG/PTCA 3 2 2 UACR, mg/g 917 633–1329 897 611–1316 1094 758–1579 Serum creatinine, m…”
Self-citationPrognosis in diabetic nephropathy.
Parving, H. H., & Hommel, E. (1989) · BMJ · doi:10.1136/bmj.299.6693.230 · Cited by 193 · cited 1×
“4/23 4/22 4/23 24-h ambulatory BP, mmHg Systolic 138 (15) 143 (15) 135 (11) Diastolic 75 (9) 75 (9) 71 (9) Clinical BP, mmHg Systolic 132 (18) 136 (14) 132 (16) Diastolic 74 (9) 72 (11) 73 (10) Prior history of myocardial infarction/CABG/PTCA 3 2 2 UACR, mg/g 917 633–1329 897 611–1316 1094 758–1579 Serum creatinine, m…”
Rossing, P., Hommel, E., Smidt, U. M., & Parving, H. H. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 192 · cited 2×
“5 Triglycerides, mg/dl 183 145–232 175 136–225 191 156–235 Total cholesterol, mg/dl 189 (49) 198 (75) 176 (44) LDL cholesterol, mg/dl 95 (38) 100 (45) 75 (29) HDL cholesterol, mg/dl 43 (10) 46 (15) 45 (11)”
van den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
Lewis, J. B., Berl, T., Bain, R. P., Rohde, R. D., & Lewis, E. J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70036-3 · Cited by 181 · cited 1×
“4/23 4/22 4/23 24-h ambulatory BP, mmHg Systolic 138 (15) 143 (15) 135 (11) Diastolic 75 (9) 75 (9) 71 (9) Clinical BP, mmHg Systolic 132 (18) 136 (14) 132 (16) Diastolic 74 (9) 72 (11) 73 (10) Prior history of myocardial infarction/CABG/PTCA 3 2 2 UACR, mg/g 917 633–1329 897 611–1316 1094 758–1579 Serum creatinine, m…”
Rossing, P., Hommel, E., Smidt, U. M., & Parving, H.-H. (1993) · Diabetes · doi:10.2337/diab.42.5.715 · Cited by 155 · cited 2×
“5 Triglycerides, mg/dl 183 145–232 175 136–225 191 156–235 Total cholesterol, mg/dl 189 (49) 198 (75) 176 (44) LDL cholesterol, mg/dl 95 (38) 100 (45) 75 (29) HDL cholesterol, mg/dl 43 (10) 46 (15) 45 (11)”
Effect of aldosterone on renal transforming growth factor-β
Juknevicius, I., Segal, Y., Kren, S. M., Lee, R., & Hostetter, T. H. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00202.2003 · Cited by 111
Diabetic nephropathy: Linking histology, cell biology, and genetics
Adler, S. G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00988.x · Cited by 103 · cited 1×
“satisfied the following criteria: (1) seated systolic BP 130 mmHg and”
BackgroundAldosterone and glomerular podocyte injury
Nagase, M., & Fujita, T. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0034-9 · Cited by 82
Aldosterone Antagonism in Chronic Kidney Disease
Ponda, M. P., & Hostetter, T. H. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00120106 · Cited by 75 · cited 1×
“4/23 4/22 4/23 24-h ambulatory BP, mmHg Systolic 138 (15) 143 (15) 135 (11) Diastolic 75 (9) 75 (9) 71 (9) Clinical BP, mmHg Systolic 132 (18) 136 (14) 132 (16) Diastolic 74 (9) 72 (11) 73 (10) Prior history of myocardial infarction/CABG/PTCA 3 2 2 UACR, mg/g 917 633–1329 897 611–1316 1094 758–1579 Serum creatinine, m…”
Zhou, X., Ono, H., Ono, Y., & Frohlich, E. D. (2004) · American Journal of Nephrology · doi:10.1159/000077396 · Cited by 66 · cited 1×
“5 Triglycerides, mg/dl 183 145–232 175 136–225 191 156–235 Total cholesterol, mg/dl 189 (49) 198 (75) 176 (44) LDL cholesterol, mg/dl 95 (38) 100 (45) 75 (29) HDL cholesterol, mg/dl 43 (10) 46 (15) 45 (11)”
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 62
Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?
Toto, R. D. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0074-4 · Cited by 14
Self-citationFox, J. C., Leight, K., Sutradhar, S., Demopoulos, L. A., Gleim, G. W., Lewin, A. J., & Bakris, G. L. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03488.x · Cited by 12
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
“MR Blockade The incorporation of MR blockade in combination with other RAAS inhibitors remains an area of great interest that has been explored in several shortterm studies with a positive effect on albuminuria reduction in DKD (53).”
Metadata
- Authors
- Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Mehdi, Uzma F.
- Adams-Huet, Beverley
- Raskin, Philip
- Toto, Robert D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-12
- Volume
- 20
- Issue
- 12
- Pages
- 2641-2650
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC2794224
- OpenAlex
- W2141386688
- Cited by
- 388
- References
- 46
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 27 · 2020: 13 · 2019: 20 · 2018: 12 · 2017: 13 · 2016: 19 · 2015: 32 · 2014: 41 · 2013: 25 · 2012: 42
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (2R01 DK6301001)
- National Center for Research Resources (M01RR000633, UL1RR024982, M01 RR00633)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- diabetic nephropathy, angiotensin receptor blockers, mineralocorticoid receptor antagonists, ACE inhibitors, lisinopril, losartan, spironolactone, albuminuria, proteinuria, renal protection, serum potassium, hypertension, albumin-creatinine ratio
- MeSH terms
- Adult, Albuminuria, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Bicarbonates, Blood Pressure, Creatinine, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypertension, Male, Middle Aged, Potassium, Renin-Angiotensin System, Spironolactone, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.